Otofarma: the Board of Directors approves the consolidated half-year financial report as at 30 June 2026 - Revenues up by 12.5% to euro 9.6 million with positive EBITDA

Protocollo
189748
Comunicato
20260929_189748.pdf
Azienda
OTOFARMA
Tipo
Comunicato
SDIR
SDIRNIS
Lingua
ENG
Data creazione
Data ricezione SDIR
Data embargo SDIR
Data diffusione SDIR
Mercato
Euronext Growth Milan